Trial Profile
A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Senju Pharmaceutical
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.
- 08 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 22 May 2018 Status changed from not yet recruiting to recruiting.